Xenon Pharmaceuticals Reports $345.9M Net Loss and Progress in Clinical Programs

**Xenon Pharmaceuticals Inc. Reports Financial Results and Operational Progress in Latest 10-K Filing**

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, released its 10-K filing, detailing its financial performance and operational activities. The company, dedicated to developing innovative therapeutics for neurological and psychiatric disorders, reported a net loss of $345.9 million for the year ended December 31, 2025, compared to net losses of $234.3 million and $182.4 million for the years ended December 31, 2024 and 2023, respectively. This increase in net loss was primarily attributed to escalating research and development expenses, as well as higher general and administrative costs. Revenue from collaboration agreements totaled $7.5 million for 2025, stemming from a milestone payment related to the company's collaboration with Neurocrine Biosciences, a significant increase from no revenue in the previous two years.

The company's research and development expenses for 2025 reached $300.9 million, a substantial increase from $210.4 million in 2024 and $167.5 million in 2023. This rise was primarily driven by the ongoing Phase 3 clinical studies of azetukalner in epilepsy, major depressive disorder (MDD), and bipolar depression (BPD). Additionally, the advancement of multiple potential drug candidates targeting Kv7, Nav1.7, and Nav1.1 also contributed to the increased spending. General and administrative expenses also saw an increase, reaching $79.6 million in 2025, compared to $68.9 million in 2024 and $46.5 million in 2023, due to higher headcount to support expanding research and development activities and future potential commercialization.

Operationally, Xenon Pharmaceuticals made significant strides in its clinical programs. The Phase 3 X-TOLE2 study of azetukalner in focal onset seizures (FOS) is on track for topline data in the first half of March 2026. Enrollment continues for the Phase 3 X-TOLE3 study in FOS, intended to support regulatory submissions outside the United States, and the Phase 3 X-ACKT study in primary generalized tonic-clonic seizures (PGTCS). Furthermore, Phase 3 studies evaluating azetukalner in MDD (X-NOVA2 and X-NOVA3) and BPD (X-CEED) are underway. The company also initiated Phase 1 studies for XEN1701 and XEN1120, targeting pain, with completion expected in 2026.

Looking ahead, Xenon Pharmaceuticals anticipates that its operating expenses will continue to increase as it progresses its clinical programs and prepares for the potential commercial launch of azetukalner. The company expects its existing cash, cash equivalents, and marketable securities, totaling $586.0 million as of December 31, 2025, will be sufficient to fund operations for at least the next 12 months. However, the company acknowledges the need for additional capital in the future to support its ongoing research and development efforts and potential commercialization activities. The company may seek to raise additional capital through public or private equity offerings, debt financings, collaborations, licensing arrangements, or other sources.